232 related articles for article (PubMed ID: 26678887)
1. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
Stanisavljević L; Aßmus J; Storli KE; Leh SM; Dahl O; Myklebust MP
Tumour Biol; 2016 Jun; 37(6):7441-52. PubMed ID: 26678887
[TBL] [Abstract][Full Text] [Related]
2. Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.
Amara S; Chaar I; Khiari M; Ounissi D; Weslati M; Boughriba R; Hmida AB; Bouraoui S
Cancer Biomark; 2015; 15(6):869-79. PubMed ID: 26406413
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
Wu W; Qian L; Chen X; Ding B
Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
[TBL] [Abstract][Full Text] [Related]
4. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
Li XF; Guo XG; Yang YY; Liu AY
Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer.
Masuda T; Nakashima Y; Ando K; Yoshinaga K; Saeki H; Oki E; Morita M; Oda Y; Maehara Y
Anticancer Res; 2014 Nov; 34(11):6397-403. PubMed ID: 25368239
[TBL] [Abstract][Full Text] [Related]
6. Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies.
Oliveira Frick V; Rubie C; Ghadjar P; Faust SK; Wagner M; Gräber S; Schilling MK
Tumour Biol; 2011 Feb; 32(1):189-96. PubMed ID: 20865359
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
8. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway.
Zhao S; Wang J; Qin C
J Exp Clin Cancer Res; 2014 Dec; 33(1):103. PubMed ID: 25471741
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma.
Rave-Fränk M; Tehrany N; Kitz J; Leu M; Weber HE; Burfeind P; Schliephake H; Canis M; Beissbarth T; Reichardt HM; Wolff HA
Strahlenther Onkol; 2016 Jan; 192(1):47-54. PubMed ID: 26374452
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients.
Ottaiano A; Scala S; Normanno N; Botti G; Tatangelo F; Di Mauro A; Capozzi M; Facchini S; Tafuto S; Nasti G
Appl Immunohistochem Mol Morphol; 2020; 28(10):755-760. PubMed ID: 31985548
[TBL] [Abstract][Full Text] [Related]
11. Chemokine (C-X-C motif) ligand 12 is associated with gallbladder carcinoma progression and is a novel independent poor prognostic factor.
Lee HJ; Lee K; Lee DG; Bae KH; Kim JS; Liang ZL; Huang SM; Suk Oh Y; Kim HY; Jo DY; Min JK; Kim JM; Lee HJ
Clin Cancer Res; 2012 Jun; 18(12):3270-80. PubMed ID: 22553346
[TBL] [Abstract][Full Text] [Related]
12. CXCL12, CXCR4 and CXCR7 expression in brain metastases.
Salmaggi A; Maderna E; Calatozzolo C; Gaviani P; Canazza A; Milanesi I; Silvani A; DiMeco F; Carbone A; Pollo B
Cancer Biol Ther; 2009 Sep; 8(17):1608-14. PubMed ID: 19625779
[TBL] [Abstract][Full Text] [Related]
13. [Significance of expression of stromal cell derived factor 1 and CXCR4 in invasive breast cancer].
Liu FF; Wei J; Lang RG; Fan Y; Cui LF; Gu F; Fu L
Zhonghua Bing Li Xue Za Zhi; 2008 Aug; 37(8):529-35. PubMed ID: 19094464
[TBL] [Abstract][Full Text] [Related]
14. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
15. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance.
van den Bosch T; Koopmans AE; Vaarwater J; van den Berg M; de Klein A; Verdijk RM
Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7354-61. PubMed ID: 24052640
[TBL] [Abstract][Full Text] [Related]
16. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
[TBL] [Abstract][Full Text] [Related]
17. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.
Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z
Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661
[TBL] [Abstract][Full Text] [Related]
18. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.
Dayer R; Babashah S; Jamshidi S; Sadeghizadeh M
J Cancer Res Ther; 2018; 14(2):345-350. PubMed ID: 29516917
[TBL] [Abstract][Full Text] [Related]
20. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.
Jiang YP; Wu XH; Shi B; Wu WX; Yin GR
Gynecol Oncol; 2006 Oct; 103(1):226-33. PubMed ID: 16631235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
